The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Flagged first, then by citations
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 601–700 of 1,053
Somatic driver mutations in melanoma
Reddy, B. Y., Miller, D. M., & Tsao, H. (2017) · Cancer · doi:10.1002/cncr.30593 · Cited by 173
Targeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 162
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
Caso, R., Sánchez-Vega, F., Tan, K. S., Mastrogiacomo, B., Zhou, J. H., Jones, G. D., Nguyen, B., Schultz, N. D., Connolly, J. G., Brandt, W. S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.005 · Cited by 158
BRAF Mutations in Canine Cancers
Mochizuki, H., Kennedy, K., Shapiro, S. G., & Breen, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129534 · Cited by 169
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells
Santini, R., Vinci, M. C., Pandolfi, S., Penachioni, J. Y., Montagnani, V., Olivito, B., Gattai, R., Pimpinelli, N., Gerlini, G., Borgognoni, L., et al. (2012) · Stem Cells · doi:10.1002/stem.1160 · Cited by 158
Store-Operated Ca2+ Entry (SOCE) Regulates Melanoma Proliferation and Cell Migration
Umemura, M., Baljinnyam, E., Feske, S., Lorenzo, M. S. D., Xie, L.-H., Feng, X., Oda, K., Makino, A., Fujita, T., Yokoyama, U., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089292 · Cited by 169
Biechele, T. L., Kulikauskas, R. M., Toroni, R. A., Lucero, O. M., Swift, R. D., James, R. G., Robin, N. C., Dawson, D. W., Moon, R. T., & Chien, A. J. (2012) · Science Signaling · doi:10.1126/scisignal.2002274 · Cited by 158
miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Díaz‐Martínez, M., Benito-Jardón, L., Alonso, L., Koetz‐Ploch, L., Hernando, E., & Teixidó, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1318 · Cited by 162
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, J. J., & Ott, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.2980 · Cited by 159
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
Vecchio, M. D., Guardo, L. D., Ascierto, P. A., Grimaldi, A. M., Chiarion‐Sileni, V., Pigozzo, J., Ferraresi, V., Nuzzo, C. M. A., Rinaldi, G., Testori, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.007 · Cited by 157
Self-citationThe biology of beta human papillomaviruses
Tommasino, M. (2016) · Virus Research · doi:10.1016/j.virusres.2016.11.013 · Cited by 166
Brady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 159
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 156
“Many of these therapies targeted mutant effectors of aberrant RTK/MAPK signaling including RAF and MEK inhibitors now used routinely to treat patients with diverse cancer types with activating BRAF mutations (28-30).”
BackgroundDesigning Transformative Clinical Trials in the Cancer Genome Era
Sleijfer, S., Bogaerts, J., & Siu, L. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3639 · Cited by 156
Mochizuki, H., Shapiro, S. G., & Breen, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144170 · Cited by 156
Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome
Hall, J. C., Baer, A. N., Shah, A. A., Criswell, L. A., Shiboski, C. H., Rosen, A., & Casciola-Rosen, L. A. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39204 · Cited by 155
Managing drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 160
Coit, D. G., Andtbacka, R. H. I., Anker, C. J., Bichakjian, C. K., Carson, W. E., DAUD, A. I., DiMaio, D. J., Fleming, M. D., Guild, V., Halpern, A. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0055 · Cited by 160
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“Cancer Cell 37, 85–103, J This is an open access article und inhibitors (BRAFi) development (Chapman et al., 2011; Flaherty et al., 2010; Zhang, 2015).”
BackgroundSelf-citationNephrotoxicity in cancer treatment: An overview
Santos, M. L. C., de Brito, B. B., da Silva, F. A. F., Botelho, A. C. D. S., & de Melo, F. F. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i4.190 · Cited by 157
Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Self-citationMAP kinase signaling and inhibition in melanoma
Sullivan, R. J., & Flaherty, K. T. (2012) · Oncogene · doi:10.1038/onc.2012.345 · Cited by 162
Self-citationTargeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M. M. J., Kroon, P., Pineda, C., Foppen, M. H. G., Scolyer, R. A., Song, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238557 · Cited by 155
Self-citationCoordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Xie, X., White, E. P., & Mehnert, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055096 · Cited by 150
The rise in metastasectomy across cancer types over the past decade
Bartlett, E. K., Simmons, K. D., Wachtel, H., Roses, R. E., Fraker, D. L., Kelz, R. R., & Karakousis, G. C. (2014) · Cancer · doi:10.1002/cncr.29134 · Cited by 153
Martinez‐García, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S. O., Kraeber‐Bodéré, F., Rojo, F., Routier, É., Guarin, E., Xu, Z., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0742 · Cited by 152
Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway
Bugaj, L. J., Sabnis, A. J., Mitchell, A., Garbarino, J. E., Toettcher, J. E., Bivona, T. G., & Lim, W. A. (2018) · Science · doi:10.1126/science.aao3048 · Cited by 153
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Self-citationPhase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
Thompson, J. F., Agarwala, S. S., Smithers, B. M., Ross, M. I., Scoggins, C. R., Coventry, B. J., Neuhaus, S. J., Minor, D. R., Singer, J. M., & Wachter, E. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4169-5 · Cited by 152
Targeted Therapy for BRAFV600E Malignant Astrocytoma
Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K. J., Baker, S. J., Paugh, B. S., Jones, C., Forshew, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1456 · Cited by 154
Cutaneous Melanoma—A Review in Detection, Staging, and Management
Hartman, R. I., & Lin, J. Y. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.09.005 · Cited by 160
From animal models to human disease: a genetic approach for personalized medicine in ALS
Picher‐Martel, V., Valdmanis, P. N., Gould, P. V., Julien, J., & Dupré, N. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0340-5 · Cited by 163
Overcoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 156
Implementing Personalized Medicine in a Cancer Center
Fenstermacher, D., Wenham, R., Rollison, D., & Dalton, W. (2011) · Cancer Journal · doi:10.1097/ppo.0b013e318238216e · Cited by 148
Grossmann, A. H., Yoo, J. H., Clancy, J. W., Sorensen, L. K., Sedgwick, A., Tong, Z., Ostanin, K., Rogers, A., Grossmann, K. F., Tripp, S. R., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003398 · Cited by 150
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V., de Groot, J., Glitza, I. C., Herlyn, M., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12538 · Cited by 150
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Ott, P. A., Carvajal, R. D., Pandit-Taskar, N., Jungbluth, A. A., Hoffman, E. W., Wu, B.-W., Bomalaski, J. S., Venhaus, R., Pan, L., Old, L. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9862-2 · Cited by 146
MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Schlegel, J., Sambade, M. J., Sather, S., Moschos, S. J., Tan, A. C., Winges, A., DeRyckere, D., Carson, C. C., Trembath, D. G., Tentler, J. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67816 · Cited by 150
Campochiaro, C., Tomelleri, A., Cavalli, G., Berti, A., & Dagna, L. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.004 · Cited by 149
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
Horbinski, C., Nikiforova, M. N., Hagenkord, J. M., Hamilton, R. L., & Pollack, I. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos077 · Cited by 149
Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
Parikh, K., Cang, S., Sekhri, A., & Liu, D. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0078-0 · Cited by 148
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A. H., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 151
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Brastianos, P. K., Twohy, E., Geyer, S., Gerstner, E. R., Kaufmann, T. J., Tabrizi, S., Kabat, B., Thierauf, J., Ruff, M. W., Bota, D. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213329 · Cited by 146
“…clinical response of BRAF V600E– mutant melanomas 14 and hairy-cell leukemia 15 to currently available BRAF inhibitors such as vemurafenib 14,16–20 and dabrafenib 21,22 prompted us to use BRAF and MEK inhibitor therapy in the treatment of a patient who presented with multiply recurrent BRAF…”
MethodHyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P. J., Baselga, J. M., Berger, M. F., & Ladanyi, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.005 · Cited by 149
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 150
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 148
Self-citationVemurafenib in pediatric patients with BRAFV 600E mutated high‐grade gliomas
Bautista, F. J., Paci, A., Minard‐Colin, V., Dufour, C., Grill, J., Lacroix, L., Varlet, P., Valteau‐Couanet, D., & Geoerger, B. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24891 · Cited by 148
Flaherty, K. T., Yasothan, U., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3579 · Cited by 148
Self-citationOncogene-like addiction to aneuploidy in human cancers
Girish, V., Lakhani, A. A., Thompson, S. L., Scaduto, C. M., Brown, L. M., Hagenson, R. A., Sausville, E. L., Mendelson, B. E., Kandikuppa, P. K., Lukow, D. A., et al. (2023) · Science · doi:10.1126/science.adg4521 · Cited by 148
Reactive Oxygen Species‐Mediated Mechanisms of Action of Targeted Cancer Therapy
Teppo, H.-R., Soini, Y., & Karihtala, P. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1485283 · Cited by 162
McCain, J. (2013) · Europe PMC (PubMed Central) · Cited by 146
Wimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 149
Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 150
Kakavand, H., Wilmott, J. S., Menzies, A. M., Vilain, R. E., Haydu, L. E., Yearley, J. H., Thompson, J. F., Kefford, R. F., Hersey, P., Long, G. V., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2023 · Cited by 148
Eigentler, T., Weide, B., de Braud, F., Spitaleri, G., Romanini, A., Pflugfelder, A., González‐Iglesias, R., Tasciotti, A., Giovannoni, L., Schwager, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1203 · Cited by 147
Self-citationBeck, D., Niessner, H., Smalley, K. S. M., Flaherty, K. T., Paraiso, K. H. T., Busch, C., Sinnberg, T. W., Vasseur, S., Iovanna, J., Drießen, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003057 · Cited by 153
Self-citationThe Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Self-citationPrasad, V. K., Kaestner, V., & Mailankody, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4182 · Cited by 144
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Schreck, K. C., Grossman, S. A., & Pratilas, C. A. (2019) · Cancers · doi:10.3390/cancers11091262 · Cited by 150
“successes as monotherapy in patients with advanced or metastatic melanoma [5,6].”
BackgroundTumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 151
“To date, these two drugs are employed, alone or in combination with chemotherapy, other targeted agents and immunotherapy in many clinical trials because they have shown to induce a substantial clinical responses and to prolong OS and progression-free survival (PFS) in melanoma patients [24,25].”
BackgroundA catalogue of somatic NRF2 gain-of-function mutations in cancer
Kerins, M. J., & Ooi, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31281-0 · Cited by 140
Halait, H., DeMartin, K., Shah, S., Soviero, S., Langland, R., Cheng, S., Hillman, G. R., Wu, L., & Lawrence, H. J. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31823b216f · Cited by 145
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 154
Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Berzofsky, J. A., Hsu, F. J., & Guitart, J. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1653-0 · Cited by 145
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 143
A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
Gautschi, O. P., Pauli, C., Strobel, K., Hirschmann, A., Printzen, G., Aebi, S. P., & Diebold, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182629903 · Cited by 141
Epidemiology of skin cancer in the mature patient
Lai, V. W. Y., Cranwell, W. C., & Sinclair, R. D. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.10.008 · Cited by 148
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 143
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
Nobre, L. F., Zápotocký, M., Ramaswamy, V., Ryall, S. T., Bennett, J., Alderete, D., Guill, J. B., Baroni, L., Bartels, U. K., Bavle, A. A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00298 · Cited by 144
Toward Explainable Artificial Intelligence for Precision Pathology
Klauschen, F., Dippel, J., Keyl, P., Jurmeister, P. S., Bockmayr, M. L., Möck, A., Buchstab, O., Alber, M., Ruff, L., Montavon, G., et al. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-113147 · Cited by 164
Niessner, H., Forschner, A., Klumpp, B. D., Honegger, J. B., Witte, M. B., Bornemann, A., Dummer, R., ADAM, A., Bauer, J. M., Tabatabai, G., et al. (2012) · Cancer Medicine · doi:10.1002/cam4.50 · Cited by 143
Self-citationChemotherapy in the management of advanced cutaneous malignant melanoma
Luke, J. J., & Schwartz, G. K. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.016 · Cited by 145
New Approaches to Molecular Diagnosis
Korf, B. R., & Rehm, H. L. (2013) · JAMA · doi:10.1001/jama.2013.3239 · Cited by 143
Bepler, G., Williams, C. C., Schell, M. J., Chen, W., Zheng, Z., Simon, G. R., Gadgeel, S. M., Zhao, X., Schreiber, F. J., Brahmer, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9783 · Cited by 141
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141
Multikinase inhibitors: a new option for the treatment of thyroid cancer
Gild, M. L., Bullock, M., Robinson, B. G., & Clifton-Bligh, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.141 · Cited by 140
Existing and Emerging Technologies for Tumor Genomic Profiling
MacConaill, L. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5948 · Cited by 144
Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
Martin, M. J., Hayward, R., Virós, A., & Marais, R. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0280 · Cited by 152
Molecular Tumor Boards: current practice and future needs
Velden, D. L. V. D., van Herpen, C. M. L., van Laarhoven, H. W. M., Smit, E. F., Groen, H. J. M., Willems, S. M., Nederlof, P. M., Langenberg, M. H. G., Cuppen, E. P. J. G., Sleijfer, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx528 · Cited by 142
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Kuan, E. C., Wang, E. W., Adappa, N. D., Beswick, D. M., London, N. R., Su, S. Y., Wang, M. B., Abuzeid, W. M., Alexiev, B. A., Alt, J. A., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23262 · Cited by 150
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Self-citationARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Cancer chemotherapy: A critical analysis of its 60 years of history
Galmarini, D., Galmarini, C. M., & Galmarini, F. C. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.002 · Cited by 142
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies, A. M., & Long, G. V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70072-5 · Cited by 145
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
Khoja, L., Lorigan, P. C., Zhou, C., Lancashire, M., Booth, J., Cummings, J., Califano, R., Clack, G., Hughes, A. M., & Dive, C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.468 · Cited by 141
Self-citationBRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Sanchez, J., Wang, T., & Cohen, M. S. (2018) · Drugs · doi:10.1007/s40265-018-0884-8 · Cited by 148
Vella, L. J., Pasam, A., Dimopoulos, N., Andrews, M., Knights, A., Puaux, A.-L., Louahed, J., Chen, W., Woods, K., & Cebon, J. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0181 · Cited by 139
Wörns, M., & Galle, P. R. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.10 · Cited by 139
Röring, M., Herr, R., Fiala, G. J., Heilmann, K., Braun, S. L., Eisenhardt, A. E., Halbach, S., Capper, D., von Deimling, A., Schamel, W. W. A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.100 · Cited by 138
Chamberlain, M. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1176-5 · Cited by 139
Kemper, K., Krijgsman, O., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Song, J., Kuilman, T., Vis, D. J., Wessels, L. F. A., Voest, E. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404914 · Cited by 141
Self-citationKrepler, C., Xiao, M., Sproesser, K., Brafford, P. A., Shannan, B., Beqiri, M., Liu, Q., Xu, W., Garman, B., Nathanson, K. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1762 · Cited by 141
Clostridium novyi-NT in cancer therapy
Staedtke, V., Roberts, N. J., Bai, R.-Y., & Zhou, S. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.01.003 · Cited by 144
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
NF-κB as potential target in the treatment of melanoma
Madonna, G., Ullmann, C. D., Gentilcore, G., Palmieri, G., & Ascierto, P. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-53 · Cited by 139
Self-citation
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
